Margaret A Chang, MD

Offices

1 location · Vitreo-Retinal Medical Group, Inc. · 21 clinicians in this group

Looking this up.

Plans that list them

9 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chang’s office at (530) 273-8358 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

9 of 9 plans

Sort by

Plans whose provider directory lists this clinician

Central Health Classic Care Plan III (HMO)	Central Health Medicare Plan	Listed	Aug 15, 2026
Central Health Dual Access Plan (HMO D-SNP)	Central Health Medicare Plan	Listed	Aug 15, 2026
Central Health Embrace Care Plan (HMO C-SNP)	Central Health Medicare Plan	Listed, may be out of date	Sep 15, 2025
Central Health Embrace Choice Plan (HMO C-SNP)	Central Health Medicare Plan	Listed	Aug 15, 2026
Central Health Valor Care Plan (HMO)	Central Health Medicare Plan	Listed	Aug 15, 2026
SCAN Balance (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Classic (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN MyChoice (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Strive (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026

California Medical Board record

Licence A103453 · Current

Licensed to practise in California · since 2008 · expires 2027-07-31 · Columbia University College of Physicians and Surgeons.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Surgery centers they own

Northern California Advanced Surgery Center LPAmbulatory Surgery Center · Sacramento, CAOwner since 2009 until 2022 · accredited by AAAHC
Accreditation Renewed5 inspections, 2 with deficiencies · last 2025-03-20: Requirements Met

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

American Board of Ophthalmology - Ophthalmology

Original Medicare doctor bills

$4,351,246

Medicare paid this office $4,351,246 for 1,563 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Injection, faricimab-svoa, 0.1 mg	158	$1,343,172	None
Injection, aflibercept, 1 mg	214	$912,052	None
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	161	$397,658	$180
Injection, aflibercept hd, 1 mg	61	$394,553	None
Injection of drug into eye	557	$222,184	$103

See all 27 services

Sort by

Every Original Medicare service billed

Injection, faricimab-svoa, 0.1 mg	158	$1,343,172	None
Injection, aflibercept, 1 mg	214	$912,052	None
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	161	$397,658	$180
Injection, aflibercept hd, 1 mg	61	$394,553	None
Injection of drug into eye	557	$222,184	$103
Injection, pegcetacoplan, intravitreal, 1 mg	28	$170,494	None
Injection, avacincaptad pegol, 0.1 mg	22	$169,479	None
Unclassified drugs	35	$148,156	None
Imaging of retina	1,443	$118,453	$33
Established patient complete exam of visual system	851	$117,984	$104
Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg	30	$66,548	$139
Injection, dexamethasone, intravitreal implant, 0.1 mg	23	$52,840	None
Established patient problem focused exam of visual system	460	$47,424	$69
Exam of retinal blood vessels using a special camera after injection of a dye	309	$46,578	$139
New patient complete exam of visual system	169	$19,989	$118
Removal of membrane of retina	12	$12,283	$1,024
Repair of detached retina with drainage and removal of eye fluid between lens and retina	11	$11,101	$1,009
Destruction of leaking blood vessels of retina using laser	23	$8,519	$284
Photocoagulation treatment to prevent detachment of retina	15	$3,062	$204
Photography of the retina	91	$2,714	$29
Short return visit (20+ min)	53	$2,395	$45
New patient problem focused exam of visual system	29	$1,802	$62
2d ultrasound scan of eye tissue and structures	25	$1,392	$42
Extended exam of the back part of the eye with optic nerve drawing	69	$895	$13
Extended exam of the back part of the eye with retinal drawing	42	$778	$19
Injection of drug or substance into membrane covering eyeball	13	$505	$39
Injection, triamcinolone acetonide, not otherwise specified, 10 mg	13	$36	None

Procedures Medicare counted

Sort by

Procedure volume Medicare published

Cataract surgery	1-10	None

Procedures year by year

Procedures billed to Original Medicare by year
Procedure	2019	2020	2021	2022	2023	2024
Injection of drug into eye	2,711	2,823	2,832	2,445	2,330	2,166
Destruction of leaking blood vessels of retina using laser	46	42	34	33	36	30
Photocoagulation treatment to prevent detachment of retina	26	18	27	27	19	15
Removal of membrane of retina with removal of internal limiting membrane of retina	24	16	23	22	33	–
Injection of drug or substance into membrane covering eyeball	31	17	15	14	18	13
Repair of detached retina with drainage and removal of eye fluid between lens and retina	18	15	25	24	14	11

Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.

Who their Medicare patients are

1,563 Original Medicare patients in 2024. Average age 77 · Under 65 5% · 85 and older 23% · Women 56% · Also on Medicaid 20% · Health risk score 1.55. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.

Conditions among them: High blood pressure 75% · Diabetes 37% · Chronic kidney disease 30% · Coronary heart disease 26% · Atrial fibrillation 19% · Heart failure 16% · COPD 16% · Depression 16% · Cancer 15% · Stroke 8% · Dementia 6%.

The office billed $15,458,190, Medicare allowed $5,531,902 and paid $4,351,246; for 67,794 services of 47 kinds; $3,555,146 of it was for drugs given in the office and $796,100 for care.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	1,563	67,794	77	1.55	$15,458,190	$4,351,246
2023	1,658	52,296	77	1.49	$15,025,020	$4,369,584
2022	1,829	22,201	77	1.49	$14,311,348	$4,010,727
2021	2,070	22,557	77	1.42	$17,984,809	$4,732,825
2020	2,138	22,759	77	1.51	$14,466,393	$4,620,479
2019	2,124	23,885	77	1.53	$12,735,493	$4,578,770
2018	2,125	24,656	77	1.55	$12,517,187	$4,736,467
2017	2,001	24,746	77	1.54	$12,897,523	$4,820,954
2016	2,212	26,703	77	1.55	$13,250,991	$5,090,135
2015	2,673	31,468	77	1.49	$14,660,598	$5,665,538
2014	2,605	32,692	77	1.45	$9,180,342	$5,311,025
2013	2,621	33,139	76	1.40	$7,048,989	$4,793,787

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 29 services

Sort by

Original Medicare services billed in 2023

Injection, aflibercept, 1 mg	311	$1,798,318	None
Injection, faricimab-svoa, 0.1 mg	113	$1,049,164	None
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	100	$266,756	$219
Injection of drug into eye	598	$230,102	$99
Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg	44	$172,101	$173
Injection, ranibizumab, 0.1 mg	71	$154,627	None
Established patient complete exam of visual system	920	$125,090	$95
Imaging of retina	1,530	$122,125	$31
Unclassified drugs	38	$121,746	None
Injection, dexamethasone, intravitreal implant, 0.1 mg	26	$66,501	None
Established patient problem focused exam of visual system	485	$47,209	$64
Exam of retinal blood vessels using a special camera after injection of a dye	333	$37,478	$110
Injection, pegcetacoplan, intravitreal, 1 mg	16	$36,108	None
Removal of membrane of retina with removal of internal limiting membrane of retina	31	$31,454	$953
New patient complete exam of visual system	201	$22,174	$110
Repair of detached retina with drainage and removal of eye fluid between lens and retina	13	$13,391	$956
Destruction of leaking blood vessels of retina using laser	32	$10,079	$280
Removal of eye fluid (vitreous) between lens and retina	14	$9,493	$678
Compounded drug, not otherwise classified	43	$5,069	None
Photocoagulation treatment to prevent detachment of retina	16	$3,924	$207
Photography of the retina	94	$2,828	$28
New patient problem focused exam of visual system	45	$2,467	$55
New patient visit (30+ min)	26	$2,289	$88
Short return visit (20+ min)	35	$2,070	$59
Extended exam of the back part of the eye with optic nerve drawing	119	$1,508	$13
2d ultrasound scan of eye tissue and structures	24	$1,439	$38
Extended exam of the back part of the eye with retinal drawing	53	$943	$17
Injection of drug or substance into membrane covering eyeball	13	$794	$44
Injection, triamcinolone acetonide, not otherwise specified, 10 mg	12	$65	None

2022: 28 services

Sort by

Original Medicare services billed in 2022

Injection, aflibercept, 1 mg	356	$2,250,978	None
Injection, ranibizumab, 0.1 mg	172	$797,654	None
Injection of drug into eye	626	$234,233	$96
Injection, faricimab-svoa, 0.1 mg	35	$141,448	None
Imaging of retina	1,672	$127,792	$31
Established patient problem focused exam of visual system	875	$87,548	$68
Exam of retinal blood vessels using a special camera after injection of a dye	551	$58,786	$98
Injection, dexamethasone, intravitreal implant, 0.1 mg	23	$55,236	None
Unclassified biologics	14	$47,225	None
Established patient complete exam of visual system	300	$30,004	$83
Short return visit (20+ min)	381	$25,224	$62
Repair of detached retina with drainage and removal of eye fluid between lens and retina	22	$23,944	$998
Removal of membrane of retina with removal of internal limiting membrane of retina	22	$20,927	$951
Compounded drug, not otherwise classified	117	$19,441	None
New patient complete exam of visual system	170	$17,817	$105
Removal of eye fluid (vitreous) between lens and retina	15	$12,030	$752
Destruction of leaking blood vessels of retina using laser	25	$8,980	$272
New patient problem focused exam of visual system	110	$6,845	$62
Photocoagulation treatment to prevent detachment of retina	22	$5,372	$199
Photography of the retina	121	$3,415	$28
New patient visit (45+ min)	24	$3,077	$128
2d ultrasound scan of eye tissue and structures	39	$1,958	$40
Extended exam of the back part of the eye with retinal drawing	81	$1,584	$19
Extended exam of the back part of the eye with optic nerve drawing	120	$1,576	$13
Return visit (30+ min)	12	$1,157	$96
New patient visit (30+ min)	13	$1,033	$79
Injection of drug or substance into membrane covering eyeball	13	$568	$41
Injection, triamcinolone acetonide, not otherwise specified, 10 mg	13	$46	None

2021: 25 services

Sort by

Original Medicare services billed in 2021

Injection, aflibercept, 1 mg	294	$2,281,966	None
Injection, ranibizumab, 0.1 mg	242	$1,391,858	None
Injection of drug into eye	682	$288,580	$102
Established patient complete exam of visual system	1,133	$148,411	$93
Imaging of retina	1,625	$137,076	$33
Established patient problem focused exam of visual system	613	$102,563	$72
Exam of retinal blood vessels using a special camera after injection of a dye	817	$89,617	$99
Injection, dexamethasone, intravitreal implant, 0.1 mg	21	$55,301	None
Compounded drug, not otherwise classified	161	$37,235	None
New patient complete exam of visual system	252	$31,317	$124
Repair of detached retina with drainage and removal of eye fluid between lens and retina	21	$25,180	$1,007
Removal of membrane of retina with removal of internal limiting membrane of retina	23	$22,269	$968
Photography of the retina	627	$20,783	$30
Removal of eye fluid (vitreous) between lens and retina	23	$16,360	$711
Photocoagulation treatment to prevent detachment of retina	25	$12,216	$452
Short return visit (20+ min)	184	$11,052	$58
Destruction of leaking blood vessels of retina using laser	28	$9,500	$279
New patient visit (45+ min)	56	$5,758	$103
New patient problem focused exam of visual system	41	$2,919	$71
Return visit (30+ min)	28	$2,436	$87
2d ultrasound scan of eye tissue and structures	43	$2,239	$41
Extended exam of the back part of the eye with retinal drawing	81	$1,635	$20
Injection of drug or substance into membrane covering eyeball	14	$595	$40
Extended exam of the back part of the eye with optic nerve drawing	35	$478	$14
Injection, triamcinolone acetonide, not otherwise specified, 10 mg	14	$55	None

2020: 26 services

Sort by

Original Medicare services billed in 2020

Injection, aflibercept, 1 mg	257	$2,067,005	None
Injection, ranibizumab, 0.1 mg	269	$1,519,421	None
Injection of drug into eye	735	$257,611	$91
Established patient complete exam of visual system	1,109	$157,649	$96
Imaging of retina	1,432	$121,116	$33
Established patient problem focused exam of visual system	749	$120,288	$70
Exam of retinal blood vessels using a special camera after injection of a dye	887	$85,343	$88
Injection, dexamethasone, intravitreal implant, 0.1 mg	26	$60,080	None
Compounded drug, not otherwise classified	239	$46,058	None
Photography of the retina	992	$39,761	$35
New patient visit (45+ min)	283	$37,136	$131
Removal of membrane of retina with removal of internal limiting membrane of retina	16	$15,742	$984
Repair of detached retina with drainage and removal of eye fluid between lens and retina	15	$15,421	$1,028
Destruction of leaking blood vessels of retina using laser	29	$12,246	$292
Photocoagulation treatment to prevent detachment of retina	18	$8,488	$472
Removal of eye fluid (vitreous) between lens and retina	11	$7,713	$701
Destruction of growth of retina using a laser	12	$5,066	$422
Short return visit (20+ min)	78	$4,560	$58
New patient visit (30+ min)	55	$4,492	$82
Return visit (30+ min)	37	$3,112	$82
2d ultrasound scan of eye tissue and structures	47	$2,326	$45
Extended exam of the back part of the eye with retinal drawing	66	$1,381	$21
Injection of drug or substance into membrane covering eyeball	16	$996	$59
Telephone medical discussion with physician, 5-10 minutes	17	$622	$37
Extended exam of the back part of the eye with optic nerve drawing	23	$304	$13
Injection, triamcinolone acetonide, not otherwise specified, 10 mg	16	$89	None

2019: 23 services

Sort by

Original Medicare services billed in 2019

Injection, aflibercept, 1 mg	204	$1,954,165	None
Injection, ranibizumab, 0.1 mg	208	$1,449,133	None
Injection of drug into eye	645	$249,704	$92
Established patient complete exam of visual system	1,395	$245,290	$99
Imaging of retina	1,429	$120,501	$33
Exam of retinal blood vessels using a special camera after injection of a dye	1,074	$99,412	$78
Established patient problem focused exam of visual system	600	$88,645	$67
Injection, dexamethasone, intravitreal implant, 0.1 mg	30	$66,889	None
Photography of the retina	1,158	$57,951	$39
Compounded drug, not otherwise classified	246	$47,164	None
New patient visit (45+ min)	373	$46,865	$126
Removal of membrane of retina with removal of internal limiting membrane of retina	23	$23,010	$959
Repair of detached retina with drainage and removal of eye fluid between lens and retina	17	$18,348	$1,019
Destruction of leaking blood vessels of retina using laser	30	$13,609	$296
Examination of eye by ophthalmoscope with retinal drawing	339	$12,311	$23
Photocoagulation treatment to prevent detachment of retina	25	$11,870	$457
Removal of eye fluid (vitreous) between lens and retina	14	$10,229	$731
New patient visit (30+ min)	39	$2,908	$75
2d ultrasound scan of eye tissue and structures	43	$2,613	$50
Injection of drug or substance into membrane covering eyeball	29	$2,218	$72
Injection, triamcinolone acetonide, preservative free, 1 mg	13	$1,933	None
Examination of eye by ophthalmoscope with retinal drawing	16	$419	$20
Injection, triamcinolone acetonide, not otherwise specified, 10 mg	29	$161	None

2018: 24 services

Sort by

Original Medicare services billed in 2018

Injection, aflibercept, 1 mg	229	$1,974,998	None
Injection, ranibizumab, 0.1 mg	220	$1,521,829	None
Established patient complete exam of visual system	1,526	$316,630	$95
Injection of drug into eye	664	$256,206	$90
Imaging of retina	1,456	$126,655	$33
Exam of retinal blood vessels using a special camera after injection of a dye	1,131	$99,433	$71
Injection, dexamethasone, intravitreal implant, 0.1 mg	29	$70,336	None
Photography of the retina	1,205	$68,911	$43
Established patient problem focused exam of visual system	480	$59,132	$72
Compounded drug, not otherwise classified	254	$43,553	None
Removal of membrane of retina with removal of internal limiting membrane of retina	31	$29,801	$961
New patient complete exam of visual system	243	$27,190	$111
Repair of detached retina with drainage and removal of eye fluid between lens and retina	22	$23,024	$1,001
Destruction of leaking blood vessels of retina using laser	45	$19,831	$279
New patient visit (45+ min)	122	$16,307	$134
Removal of eye fluid (vitreous) between lens and retina	24	$16,204	$675
Examination of eye by ophthalmoscope with retinal drawing	295	$10,175	$22
Photocoagulation treatment to prevent detachment of retina	20	$8,826	$441
2d ultrasound scan of eye tissue and structures	49	$4,411	$64
Injection of drug or substance into membrane covering eyeball	23	$2,025	$81
New patient problem focused exam of visual system	26	$1,583	$61
Examination of eye by ophthalmoscope with retinal drawing	35	$945	$19
Short return visit (20+ min)	11	$596	$54
Injection, triamcinolone acetonide, not otherwise specified, 10 mg	23	$143	None

2017: 25 services

Sort by

Original Medicare services billed in 2017

Injection, aflibercept, 1 mg	235	$1,996,708	None
Injection, ranibizumab, 0.1 mg	218	$1,554,008	None
Established patient complete exam of visual system	1,560	$389,210	$100
Injection of drug into eye	658	$259,571	$91
Imaging of retina	1,440	$130,835	$34
Exam of retinal blood vessels using a special camera after injection of a dye	1,062	$86,452	$65
Photography of the retina	1,114	$80,989	$56
Injection, dexamethasone, intravitreal implant, 0.1 mg	25	$48,455	None
Compounded drug, not otherwise classified	261	$44,564	None
New patient complete exam of visual system	278	$33,440	$120
Removal of membrane of retina with removal of internal limiting membrane of retina	30	$30,465	$952
Repair of detached retina with drainage and removal of eye fluid between lens and retina	28	$29,749	$992
Established patient problem focused exam of visual system	248	$25,779	$69
Removal of eye fluid (vitreous) between lens and retina	27	$18,215	$675
Destruction of leaking blood vessels of retina using laser	36	$15,272	$288
Photocoagulation treatment to prevent detachment of retina	23	$11,061	$442
Examination of eye by ophthalmoscope with retinal drawing	193	$6,689	$22
2d ultrasound scan of eye tissue and structures	45	$4,166	$77
Injection of drug or substance into membrane covering eyeball	36	$3,654	$83
Injection, triamcinolone acetonide, preservative free, 1 mg	12	$2,664	None
New patient problem focused exam of visual system	33	$2,152	$65
Return visit (30+ min)	19	$2,002	$87
Short return visit (20+ min)	25	$1,348	$54
Examination of eye by ophthalmoscope with retinal drawing	39	$1,054	$20
Injection, triamcinolone acetonide, not otherwise specified, 10 mg	36	$266	None

2016: 29 services

Sort by

Original Medicare services billed in 2016

Injection, aflibercept, 1 mg	276	$2,424,444	None
Injection, ranibizumab, 0.1 mg	174	$1,190,063	None
Established patient complete exam of visual system	1,456	$293,910	$99
Injection of drug into eye	787	$291,655	$92
Exam of retinal blood vessels using a special camera after injection of a dye	1,168	$231,983	$89
Imaging of retina	1,543	$154,587	$37
Established patient problem focused exam of visual system	742	$97,762	$67
Photography of the retina	1,186	$85,156	$59
Compounded drug, not otherwise classified	390	$67,961	None
Injection, dexamethasone, intravitreal implant, 0.1 mg	20	$47,265	None
New patient complete exam of visual system	294	$34,779	$118
Removal of membrane of retina with removal of internal limiting membrane of retina	27	$25,690	$918
Repair of detached retina with drainage and removal of eye fluid between lens and retina	23	$24,712	$1,074
Destruction of leaking blood vessels of retina using laser	41	$19,339	$280
Removal of eye fluid (vitreous) between lens and retina	21	$14,561	$693
Photocoagulation treatment to prevent detachment of retina	26	$12,200	$436
Destruction of eye fluid (vitreous) between lens and retina and all of retina using a laser	12	$9,503	$792
Examination of eye by ophthalmoscope with retinal drawing	251	$8,764	$22
Short return visit (20+ min)	113	$6,170	$54
Destruction of growth of retina using a laser	13	$5,565	$428
2d ultrasound scan of eye tissue and structures	41	$3,708	$77
Aspiration of lens material by fragmenting and aspiration	11	$3,612	$328
New patient problem focused exam of visual system	55	$3,307	$60
Injection, triamcinolone acetonide, preservative free, 1 mg	11	$2,398	None
Injection of drug or substance into membrane covering eyeball	22	$1,928	$77
Return visit (30+ min)	22	$1,927	$80
New patient visit (45+ min)	11	$1,479	$134
Examination of eye by ophthalmoscope with retinal drawing	28	$655	$19
Injection, triamcinolone acetonide, not otherwise specified, 10 mg	21	$135	None

2015: 29 services

Sort by

Original Medicare services billed in 2015

Injection, aflibercept, 1 mg	331	$2,808,838	None
Injection, ranibizumab, 0.1 mg	141	$1,088,878	None
Injection of drug into eye	853	$320,941	$92
Exam of retinal blood vessels using a special camera after injection of a dye	1,440	$303,144	$88
Established patient complete exam of visual system	1,421	$261,012	$98
Imaging of retina	1,758	$171,824	$37
Established patient problem focused exam of visual system	1,132	$158,402	$66
Photography of the retina	1,452	$107,229	$58
Destruction of leaking blood vessels of retina using laser	72	$94,912	$840
New patient complete exam of visual system	455	$54,018	$119
Removal of membrane of retina with removal of internal limiting membrane of retina	45	$43,786	$932
Unclassified biologics	289	$39,182	None
Compounded Drug, Not Otherwise Classified	285	$37,649	$55
Injection, dexamethasone, intravitreal implant, 0.1 mg	19	$33,073	None
Repair of detached retina with drainage and removal of eye fluid between lens and retina	12	$18,558	$1,326
Destruction of growth of retina using a laser	27	$14,827	$436
Removal of eye fluid (vitreous) between lens and retina	19	$14,533	$727
Examination of eye by ophthalmoscope with retinal drawing	400	$14,123	$23
Short return visit (20+ min)	180	$10,800	$58
Photocoagulation treatment to prevent detachment of retina	18	$7,937	$441
Injection, triamcinolone acetonide, preservative free, 1 mg	25	$5,948	None
2d ultrasound scan of eye tissue and structures	51	$4,646	$76
Return visit (30+ min)	50	$4,528	$87
Injection of drug or substance into membrane covering eyeball	37	$3,339	$86
New patient visit (45+ min)	18	$2,221	$123
New patient problem focused exam of visual system	35	$2,113	$60
Examination of eye by ophthalmoscope with retinal drawing	66	$1,796	$20
Injection, bevacizumab, 10 mg	16	$1,028	None
Injection, triamcinolone acetonide, not otherwise specified, 10 mg	37	$239	None

2014: 29 services

Sort by

Original Medicare services billed in 2014

Injection, aflibercept, 1 mg	260	$2,213,857	None
Injection, ranibizumab, 0.1 mg	170	$1,283,265	None
Injection of drug into eye	837	$340,120	$93
Exam of retinal blood vessels using a special camera after injection of a dye	1,444	$308,135	$88
Established patient complete exam of visual system	1,348	$233,377	$95
Established patient problem focused exam of visual system	1,242	$174,592	$66
Imaging of retina	1,744	$170,767	$37
Destruction of leaking blood vessels of retina using laser	81	$106,729	$840
Photography of the retina	1,438	$106,540	$58
Unclassified biologics	510	$89,105	None
Removal of membrane of retina with removal of internal limiting membrane of retina	50	$62,715	$1,254
New patient complete exam of visual system	453	$53,975	$119
Repair of detached retina with drainage and removal of eye fluid between lens and retina	19	$24,224	$1,275
Destruction of eye fluid (vitreous) between lens and retina and all of retina using a laser	19	$22,972	$1,149
Examination of eye by ophthalmoscope with retinal drawing	439	$15,665	$23
Destruction of growth of retina using a laser	28	$14,002	$438
Removal of eye fluid (vitreous) between lens and retina	15	$12,493	$781
Photocoagulation treatment to prevent detachment of retina	17	$8,465	$446
Injection, triamcinolone acetonide, preservative free, 1 mg	29	$8,213	None
Exam of blood vessels between the white part of eye and retina using a special camera after injection of a dye	30	$6,510	$210
2d ultrasound scan of eye tissue and structures	45	$3,851	$77
Examination of eye by ophthalmoscope with retinal drawing	138	$3,566	$19
Short return visit (20+ min)	65	$2,936	$44
Injection of drug or substance into membrane covering eyeball	27	$2,579	$83
Return visit (30+ min)	29	$2,499	$78
New patient visit (45+ min)	21	$2,487	$118
New patient visit (30+ min)	31	$2,472	$80
New patient problem focused exam of visual system	35	$2,154	$62
Injection, triamcinolone acetonide, not otherwise specified, 10 mg	27	$185	None

2013: 30 services

Sort by

Original Medicare services billed in 2013

Injection, aflibercept, 1 mg	217	$2,121,015	None
Injection, ranibizumab, 0.1 mg	124	$846,666	None
Exam of retinal blood vessels using a special camera after injection of a dye	1,540	$350,601	$90
Injection of drug into eye	770	$309,716	$91
Imaging of retina	1,674	$163,467	$36
Established patient problem focused exam of visual system	1,379	$153,312	$65
Established patient complete exam of visual system	1,123	$151,807	$94
Photography of the retina	1,549	$127,021	$59
Destruction of leaking blood vessels of retina using laser	78	$107,579	$834
Unclassified biologics	498	$70,923	None
Short return visit (20+ min)	788	$68,117	$56
Removal of membrane of retina with removal of internal limiting membrane of retina	44	$56,257	$1,250
New patient complete exam of visual system	295	$36,274	$123
Repair of detached retina with drainage and removal of eye fluid between lens and retina	18	$25,237	$1,328
Destruction of eye fluid (vitreous) between lens and retina and all of retina using a laser	17	$21,298	$1,183
Removal of eye fluid (vitreous) between lens and retina	25	$20,759	$798
Destruction of growth of retina using a laser	38	$18,982	$441
Examination of eye by ophthalmoscope with retinal drawing	531	$18,832	$22
Return visit (30+ min)	169	$12,199	$70
Photocoagulation treatment to prevent detachment of retina	24	$11,076	$426
Injection, triamcinolone acetonide, preservative free, 1 mg	38	$10,048	None
New patient problem focused exam of visual system	142	$9,569	$67
New patient visit (45+ min)	80	$8,220	$103
New patient visit (30+ min)	95	$7,242	$76
Examination of eye by ophthalmoscope with retinal drawing	198	$7,120	$19
2d ultrasound scan of eye tissue and structures	63	$6,598	$78
Exam of blood vessels between the white part of eye and retina using a special camera after injection of a dye	33	$6,216	$178
Injection of drug or substance into membrane covering eyeball	40	$3,906	$85
Short return visit	15	$551	$37
Injection, triamcinolone acetonide, not otherwise specified, 10 mg	40	$282	None

Medicaid work

$12,117 in 2024

Medicaid paid $12,117 for 490 billed services this clinician did in 2024, up to 25 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Sort by

Largest Medicaid services in 2024

Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina	401	$6,915
Intravitreal injection of a pharmacologic agent (separate procedure)	89	$5,202

Sort by

Medicaid work by year

2024	490	2	25	$12,117
2023	911	4	28	$52,352
2022	522	3	25	$16,982
2021	1,144	4	30	$112,347
2020	1,005	5	27	$87,339
2019	540	5	21	$23,039
2018	483	6	21	$35,764

See the largest Medicaid services in earlier years

2023

Sort by

Largest Medicaid services in 2023

Intravitreal injection of a pharmacologic agent (separate procedure)	246	$27,977
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina	638	$17,286
Aflibercept injection	14	$6,717
Short return visit (20+ min)	13	$372

2022

Sort by

Largest Medicaid services in 2022

Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina	400	$9,257
Aflibercept injection	12	$4,751
Intravitreal injection of a pharmacologic agent (separate procedure)	110	$2,974

2021

Sort by

Largest Medicaid services in 2021

Intravitreal injection of a pharmacologic agent (separate procedure)	360	$86,404
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina	711	$22,193
FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI	24	$1,992
Short return visit (20+ min)	49	$1,758

2020

Sort by

Largest Medicaid services in 2020

Intravitreal injection of a pharmacologic agent (separate procedure)	327	$64,242
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina	443	$11,626
FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI	72	$4,853
FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT	95	$3,477
Return visit (30+ min)	68	$3,140

2019

Sort by

Largest Medicaid services in 2019

Intravitreal injection of a pharmacologic agent (separate procedure)	148	$12,803
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina	287	$4,657
FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI	30	$2,657
FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT	43	$1,614
Return visit (30+ min)	32	$1,309

2018

Sort by

Largest Medicaid services in 2018

Intravitreal injection of a pharmacologic agent (separate procedure)	152	$21,162
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina	223	$9,045
Return visit (30+ min)	55	$3,984
FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI	12	$849
FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT	25	$678
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST	16	$46

Drugs they prescribed that Part D paid

$24,597

Pharmacies billed $24,597 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

374 generic and 207 brand-name prescriptions · $24,597 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Ketorolac Tromethamine	201	$6,404	$32
Prednisolone Acetate	122	$5,886	$48
Brimonidine Tartrate-Timolol	13	$1,198	$92
Ofloxacin	95	$1,136	$12
Brimonidine	20	$696	$35

See all 7 drugs

Sort by

Every Part D drug this clinician prescribed

Ketorolac Tromethamine	201	$6,404	$32
Prednisolone Acetate	122	$5,886	$48
Brimonidine Tartrate-Timolol	13	$1,198	$92
Ofloxacin	95	$1,136	$12
Brimonidine	20	$696	$35
Latanoprost	50	$543	$11
Dorzolamide	14	$244	$17

Year by year

Sort by

Part D prescribing by year

2024	581	207	None	36%	$24,597
2023	595	214	0% (0)	38%	$38,725
2022	611	223	None	36%	$35,097
2021	623	215	None	39%	$37,796
2020	563	218	None	32%	$28,975
2019	527	211	None	34%	$30,704
2018	604	229	None	36%	$34,418
2017	553	198	None	40%	$29,936
2016	488	207	None	34%	$25,423
2015	614	230	None	43%	$36,068
2014	616	226	None	41%	$33,934
2013	502	197	None	None	$23,865

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 8 drugs

Sort by

Part D drugs prescribed in 2023

Prednisolone Acetate	132	$7,407	$56
Ketorolac Tromethamine	172	$5,790	$34
Combigan	14	$3,922	$280
Ofloxacin	88	$1,308	$15
Latanoprost	43	$1,214	$28
Dorzolamide-Timolol	23	$725	$32
Brimonidine	27	$465	$17
Timolol Maleate	27	$401	$15

2022: 9 drugs

Sort by

Part D drugs prescribed in 2022

Prednisolone Acetate	137	$7,161	$52
Ketorolac Tromethamine	164	$5,461	$33
Lumigan	11	$2,928	$266
Ofloxacin	102	$1,297	$13
Latanoprost	49	$1,200	$24
Dorzolamide-Timolol	24	$580	$24
Brimonidine	34	$571	$17
Timolol Maleate	26	$418	$16
Dorzolamide	11	$285	$26

2021: 10 drugs

Sort by

Part D drugs prescribed in 2021

Prednisolone Acetate	131	$8,329	$64
Combigan	26	$6,130	$236
Ketorolac Tromethamine	138	$4,946	$36
Lumigan	19	$4,577	$241
Latanoprost	64	$1,572	$25
Ofloxacin	80	$1,115	$14
Brimonidine	37	$635	$17
Dorzolamide	16	$575	$36
Timolol Maleate	35	$405	$12
Dorzolamide-Timolol	13	$352	$27

2020: 7 drugs

Sort by

Part D drugs prescribed in 2020

Combigan	28	$6,914	$247
Prednisolone Acetate	107	$6,396	$60
Ketorolac Tromethamine	114	$4,012	$35
Brimonidine	54	$2,487	$46
Ofloxacin	80	$1,201	$15
Latanoprost	46	$1,079	$23
Timolol Maleate	42	$773	$18

2019: 8 drugs

Sort by

Part D drugs prescribed in 2019

Combigan	28	$6,827	$244
Prednisolone Acetate	95	$6,192	$65
Ketorolac Tromethamine	154	$5,001	$32
Tobramycin-Dexamethasone	11	$1,250	$114
Ofloxacin	81	$1,241	$15
Brimonidine	26	$546	$21
Latanoprost	23	$427	$19
Timolol Maleate	29	$219	$8

2018: 8 drugs

Sort by

Part D drugs prescribed in 2018

Combigan	42	$8,062	$192
Prednisolone Acetate	107	$7,089	$66
Ketorolac Tromethamine	190	$5,077	$27
Ofloxacin	81	$1,142	$14
Latanoprost	42	$781	$19
Dorzolamide	13	$559	$43
Timolol Maleate	42	$379	$9
Brimonidine	21	$360	$17

2017: 9 drugs

Sort by

Part D drugs prescribed in 2017

Combigan	40	$5,927	$148
Prednisolone Acetate	96	$5,396	$56
Lumigan	19	$4,287	$226
Ketorolac Tromethamine	136	$3,264	$24
Ofloxacin	81	$1,217	$15
Latanoprost	53	$566	$11
Timolol Maleate	29	$325	$11
Brimonidine	11	$97	$9
Simvastatin	11	$57	$5

2016: 10 drugs

Sort by

Part D drugs prescribed in 2016

Combigan	33	$4,974	$151
Ketorolac Tromethamine	130	$4,006	$31
Prednisolone Acetate	66	$3,963	$60
Lumigan	17	$2,895	$170
Ofloxacin	62	$1,077	$17
Brimonidine	11	$569	$52
Latanoprost	33	$405	$12
Dorzolamide	18	$374	$21
Timolol Maleate	18	$122	$7
Simvastatin	14	$73	$5

2015: 12 drugs

Sort by

Part D drugs prescribed in 2015

Prednisolone Acetate	148	$10,839	$73
Lumigan	23	$4,721	$205
Spiriva	11	$3,750	$341
Ketorolac Tromethamine	116	$3,226	$28
Combigan	21	$2,568	$122
Vigamox	17	$2,273	$134
Ofloxacin	97	$1,697	$17
Brimonidine	18	$417	$23
Latanoprost	21	$293	$14
Dorzolamide	13	$254	$20
Timolol Maleate	34	$238	$7
Spironolactone	13	$179	$14

2014: 6 drugs

Sort by

Part D drugs prescribed in 2014

Prednisolone Acetate	121	$8,476	$70
Vigamox	65	$7,057	$109
Ketorolac Tromethamine	221	$4,465	$20
Ofloxacin	34	$583	$17
Timolol Maleate	38	$304	$8
Latanoprost	11	$176	$16

2013: 6 drugs

Sort by

Part D drugs prescribed in 2013

Vigamox	85	$8,670	$102
Ketorolac Tromethamine	158	$3,453	$22
Prednisolone Acetate	107	$2,959	$28
Dorzolamide	13	$515	$40
Latanoprost	26	$495	$19
Timolol Maleate	31	$251	$8

Money from drug and device companies

$82,401 in 2025

Sort by

Industry payments by year

2025	14	82	$62,411	$82,401
2024	17	72	$56,207	$68,720
2023	9	35	$500	$2,425
2022	8	27	$21,684	$22,441
2021	2	9	$3,245	$3,425
2020	6	10	$6,020	$6,246
2019	7	16	$10,226	$11,617

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Genentech USA	Vabysmo	$23,081	17 payments Meals for Susvimo · 2025-11-18 · $28 Meals for Susvimo · 2025-10-31 · $24 Paid to speak or teach for Susvimo · 2025-10-17 · $2,700 Consulting for Vabysmo · 2025-09-11 · $9,200 Meals for Vabysmo · 2025-09-02 · $28 Meals for Susvimo · 2025-07-11 · $16 Meals for Vabysmo · 2025-07-08 · $25 Meals for Susvimo · 2025-06-13 · $27 Paid to speak or teach for Susvimo · 2025-05-22 · $2,700 Meals for Susvimo · 2025-05-22 · $150 Meals for Vabysmo · 2025-03-31 · $29 Meals for Vabysmo · 2025-03-25 · $26 Consulting for Vabysmo · 2025-02-26 · $3,375 Paid to speak or teach for Susvimo · 2025-02-06 · $2,700 Meals for Vabysmo · 2025-01-15 · $29 Consulting for Susvimo · 2025-01-09 · $338 Consulting for Susvimo · 2025-01-09 · $1,688
Roche Products	None	$17,709	5 payments Travel · 2025-10-01 · $437 Travel · 2025-10-01 · $173 Consulting · 2025-10-01 · $7,140 Travel · 2025-10-01 · $9,835 Meals · 2025-10-01 · $123
Boehringer Ingelheim International GmbH	None	$17,562	11 payments Consulting · 2025-09-24 · $950 Consulting · 2025-09-11 · $2,850 Consulting · 2025-09-04 · $475 Travel · 2025-06-04 · $39 Paid to speak or teach · 2025-06-04 · $370 Travel · 2025-06-04 · $707 Consulting · 2025-05-14 · $950 Consulting · 2025-05-14 · $950 Travel · 2025-02-12 · $96 Consulting · 2025-02-12 · $3,800 Travel · 2025-02-12 · $6,375
Genentech	Lucentis	$11,162	5 payments Consulting for Lucentis · 2025-12-05 · $7,140 Consulting for Lucentis · 2025-07-17 · $1,680 Meals · 2025-06-05 · $121 Consulting for Lucentis · 2025-04-18 · $2,100 Meals for Vabysmo · 2025-04-17 · $122
Ocular Therapeutix	Dextenza	$10,960	13 payments Meals for Dextenza · 2025-10-17 · $74 Consulting · 2025-08-11 · $1,000 Meals for Dextenza · 2025-07-31 · $8 Paid to speak or teach · 2025-06-21 · $2,500 Consulting · 2025-06-20 · $1,833 Consulting · 2025-05-29 · $1,000 Meals for Dextenza · 2025-04-29 · $30 Consulting · 2025-03-25 · $1,000 Consulting · 2025-03-18 · $1,000 Consulting · 2025-03-02 · $1,000 Meals for Dextenza · 2025-01-22 · $15 Consulting · 2025-01-20 · $1,000 Consulting · 2025-01-20 · $500
Apellis Pharmaceuticals	Syfovre	$1,015	11 payments Meals for Syfovre · 2025-12-17 · $33 Meals for Syfovre · 2025-11-10 · $34 Meals for Syfovre · 2025-10-29 · $30 Meals for Syfovre · 2025-09-10 · $28 Meals for Syfovre · 2025-08-02 · $63 Meals for Syfovre · 2025-06-19 · $120 Meals for Syfovre · 2025-06-10 · $27 Meals for Syfovre · 2025-06-04 · $153 Meals for Syfovre · 2025-05-15 · $25 Meals for Syfovre · 2025-03-12 · $29 Consulting for Syfovre · 2025-02-21 · $473

See all 82 published payments

Sort by

Every published payment

Apellis Pharmaceuticals	Meals · 2025-12-17	Syfovre	$33
Astellas Pharma US	Meals · 2025-12-16	Izervay	$15
Genentech	Consulting · 2025-12-05	Lucentis	$7,140
Mallinckrodt Hospital Products	Meals · 2025-12-03	Acthar	$27
Genentech USA	Meals · 2025-11-18	Susvimo	$28
Apellis Pharmaceuticals	Meals · 2025-11-10	Syfovre	$34
Genentech USA	Meals · 2025-10-31	Susvimo	$24
Apellis Pharmaceuticals	Meals · 2025-10-29	Syfovre	$30
Genentech USA	Paid to speak or teach · 2025-10-17	Susvimo	$2,700
Ocular Therapeutix	Meals · 2025-10-17	Dextenza	$74
Roche Products	Travel · 2025-10-01	None	$437
Roche Products	Travel · 2025-10-01	None	$173
Roche Products	Consulting · 2025-10-01	None	$7,140
Roche Products	Travel · 2025-10-01	None	$9,835
Roche Products	Meals · 2025-10-01	None	$123
Mallinckrodt Hospital Products	Meals · 2025-09-24	Acthar	$33
Boehringer Ingelheim International GmbH	Consulting · 2025-09-24	None	$950
Astellas Pharma US	Meals · 2025-09-17	Izervay	$8
Astellas Pharma US	Meals · 2025-09-17	Izervay	$11
Astellas Pharma US	Meals · 2025-09-15	Izervay	$4
Genentech USA	Consulting · 2025-09-11	Vabysmo	$9,200
Boehringer Ingelheim International GmbH	Consulting · 2025-09-11	None	$2,850
Apellis Pharmaceuticals	Meals · 2025-09-10	Syfovre	$28
Boehringer Ingelheim International GmbH	Consulting · 2025-09-04	None	$475
Genentech USA	Meals · 2025-09-02	Vabysmo	$28
Ocular Therapeutix	Consulting · 2025-08-11	None	$1,000
Astellas Pharma US	Meals · 2025-08-06	Izervay	$21
Apellis Pharmaceuticals	Meals · 2025-08-02	Syfovre	$63
Ocular Therapeutix	Meals · 2025-07-31	Dextenza	$8
Genentech	Consulting · 2025-07-17	Lucentis	$1,680
Genentech USA	Meals · 2025-07-11	Susvimo	$16
Genentech USA	Meals · 2025-07-08	Vabysmo	$25
Harrow Eye	Meals · 2025-06-25	Iheezo	$26
Ocular Therapeutix	Paid to speak or teach · 2025-06-21	None	$2,500
Ocular Therapeutix	Consulting · 2025-06-20	None	$1,833
Apellis Pharmaceuticals	Meals · 2025-06-19	Syfovre	$120
Harrow Eye	Meals · 2025-06-17	Iheezo	$107
Genentech USA	Meals · 2025-06-13	Susvimo	$27
Apellis Pharmaceuticals	Meals · 2025-06-10	Syfovre	$27
Genentech	Meals · 2025-06-05	None	$121
Boehringer Ingelheim International GmbH	Travel · 2025-06-04	None	$39
Boehringer Ingelheim International GmbH	Paid to speak or teach · 2025-06-04	None	$370
Boehringer Ingelheim International GmbH	Travel · 2025-06-04	None	$707
Apellis Pharmaceuticals	Meals · 2025-06-04	Syfovre	$153
Ocular Therapeutix	Consulting · 2025-05-29	None	$1,000
Genentech USA	Paid to speak or teach · 2025-05-22	Susvimo	$2,700
Genentech USA	Meals · 2025-05-22	Susvimo	$150
Astellas Pharma Global Development	Meals · 2025-05-20	Izervay	$30
Apellis Pharmaceuticals	Meals · 2025-05-15	Syfovre	$25
Boehringer Ingelheim International GmbH	Consulting · 2025-05-14	None	$950
Boehringer Ingelheim International GmbH	Consulting · 2025-05-14	None	$950
Regeneron Pharmaceuticals	Meals · 2025-05-06	Eylea Hd	$103
Astellas Pharma US	Meals · 2025-05-06	Izervay	$40
ANI Pharmaceuticals	Meals · 2025-04-30	Yutiq	$29
Ocular Therapeutix	Meals · 2025-04-29	Dextenza	$30
Astellas Pharma US	Meals · 2025-04-21	Izervay	$70
Genentech	Consulting · 2025-04-18	Lucentis	$2,100
Genentech	Meals · 2025-04-17	Vabysmo	$122
Amgen	Meals · 2025-04-15	Pavblu	$21
Genentech USA	Meals · 2025-03-31	Vabysmo	$29
Genentech USA	Meals · 2025-03-25	Vabysmo	$26
Ocular Therapeutix	Consulting · 2025-03-25	None	$1,000
Abbvie	Meals · 2025-03-20	Ozurdex	$29
Ocular Therapeutix	Consulting · 2025-03-18	None	$1,000
Apellis Pharmaceuticals	Meals · 2025-03-12	Syfovre	$29
Ocular Therapeutix	Consulting · 2025-03-02	None	$1,000
Genentech USA	Consulting · 2025-02-26	Vabysmo	$3,375
Apellis Pharmaceuticals	Consulting · 2025-02-21	Syfovre	$473
Regeneron Pharmaceuticals	Meals · 2025-02-13	Eylea Hd	$74
Boehringer Ingelheim International GmbH	Travel · 2025-02-12	None	$96
Boehringer Ingelheim International GmbH	Consulting · 2025-02-12	None	$3,800
Boehringer Ingelheim International GmbH	Travel · 2025-02-12	None	$6,375
Genentech USA	Paid to speak or teach · 2025-02-06	Susvimo	$2,700
Regeneron Pharmaceuticals	Meals · 2025-01-22	Eylea Hd	$26
Ocular Therapeutix	Meals · 2025-01-22	Dextenza	$15
Astellas Pharma US	Meals · 2025-01-21	Izervay	$95
Ocular Therapeutix	Consulting · 2025-01-20	None	$1,000
Ocular Therapeutix	Consulting · 2025-01-20	None	$500
Genentech USA	Meals · 2025-01-15	Vabysmo	$29
Genentech USA	Consulting · 2025-01-09	Susvimo	$338
Genentech USA	Consulting · 2025-01-09	Susvimo	$1,688
Amgen	Meals · 2025-01-08	Pavblu	$144

See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $68,720

Sort by

Payments by company in 2024

Genentech	None	$16,705	3 payments Consulting · 2024-11-26 · $1,680 Consulting · 2024-09-19 · $6,390 Consulting · 2024-08-22 · $8,635
F. Hoffmann-La Roche AG	None	$15,515	5 payments Travel · 2024-09-21 · $8,281 Consulting · 2024-09-21 · $5,040 Meals · 2024-09-21 · $78 Consulting · 2024-09-19 · $2,100 Meals · 2024-09-19 · $17
Ocular Therapeutix	Dextenza	$15,051	9 payments Consulting · 2024-12-10 · $1,000 Consulting · 2024-11-01 · $1,500 Consulting · 2024-10-07 · $2,000 Consulting · 2024-10-07 · $1,000 Consulting · 2024-10-07 · $1,000 Consulting · 2024-07-08 · $1,500 Consulting · 2024-07-08 · $2,000 Consulting · 2024-05-22 · $5,000 Meals for Dextenza · 2024-01-16 · $51
Genentech USA	Susvimo	$8,986	13 payments Paid to speak or teach for Susvimo · 2024-12-06 · $3,360 Meals for Vabysmo · 2024-12-03 · $34 Meals for Susvimo · 2024-09-27 · $30 Meals for Vabysmo · 2024-09-24 · $28 Paid to speak or teach for Susvimo · 2024-08-22 · $3,360 Consulting for Susvimo · 2024-08-09 · $1,350 Meals for Susvimo · 2024-08-06 · $31 Paid to speak or teach for Susvimo · 2024-07-11 · $660 Meals for Vabysmo · 2024-06-12 · $26 Meals for Vabysmo · 2024-03-04 · $32 Meals for Susvimo · 2024-02-13 · $28 Meals for Vabysmo · 2024-02-06 · $25 Meals for Vabysmo · 2024-01-02 · $23
Abbvie	Ozurdex	$2,469	3 payments Consulting · 2024-08-05 · $2,400 Meals · 2024-07-18 · $37 Meals for Ozurdex · 2024-07-10 · $32
Astellas Pharma Global Development	Izervay	$2,382	1 payment Consulting for Izervay · 2024-07-24 · $2,382
EyePoint Pharmaceuticals US	Eyp-1901	$2,055	5 payments Travel for Eyp-1901 · 2024-11-19 · $101 Travel for Eyp-1901 · 2024-11-16 · $799 Travel for Eyp-1901 · 2024-11-16 · $730 Meals for Eyp-1901 · 2024-11-16 · $206 Meals for Eyp-1901 · 2024-11-16 · $219
Carl Zeiss Meditec	Cirrus 6000 With Angioplex	$2,025	2 payments Consulting for Cirrus 6000 With Angioplex · 2024-06-05 · $1,215 Consulting for Cirrus Hd-Oct · 2024-04-24 · $810
Boehringer Ingelheim International GmbH	None	$1,325	2 payments Consulting · 2024-11-27 · $530 Consulting · 2024-09-27 · $795
Astellas Pharma US	Izervay	$1,019	8 payments Meals for Izervay · 2024-12-03 · $88 Meals for Izervay · 2024-10-24 · $34 Meals for Izervay · 2024-08-23 · $35 Meals for Izervay · 2024-08-21 · $120 Meals for Izervay · 2024-05-13 · $54 Meals for Izervay · 2024-04-29 · $90 Meals for Izervay · 2024-01-10 · $97 Consulting for Izervay · 2024-01-06 · $500
Apellis Pharmaceuticals	Syfovre	$528	9 payments Meals for Syfovre · 2024-11-13 · $33 Meals for Syfovre · 2024-10-15 · $33 Meals for Syfovre · 2024-09-11 · $117 Meals for Syfovre · 2024-08-23 · $108 Meals for Syfovre · 2024-06-25 · $29 Meals for Syfovre · 2024-04-17 · $35 Meals for Syfovre · 2024-03-14 · $35 Meals for Syfovre · 2024-03-14 · $105 Meals for Syfovre · 2024-01-10 · $34
Regeneron Healthcare Solutions	Eylea Hd	$411	5 payments Meals for Eylea Hd · 2024-11-23 · $120 Meals for Eylea Hd · 2024-08-27 · $3 Meals for Eylea Hd · 2024-08-26 · $18 Meals for Eylea Hd · 2024-07-13 · $113 Meals for Eylea · 2024-04-05 · $158
Regeneron Pharmaceuticals	Eylea Hd	$93	2 payments Meals for Eylea Hd · 2024-09-20 · $30 Meals for Eylea Hd · 2024-01-16 · $64
Topcon Healthcare	None	$60	1 payment Meals · 2024-09-11 · $60
Amgen	Pavblu	$50	2 payments Meals for Pavblu · 2024-11-05 · $26 Meals · 2024-08-13 · $24
Harrow Eye	Iheezo	$28	1 payment Meals for Iheezo · 2024-11-11 · $28
Biogen	Byooviz	$18	1 payment Meals for Byooviz · 2024-01-30 · $18

2023: $2,425

Sort by

Payments by company in 2023

Genentech USA	Susvimo	$799	10 payments Travel for Susvimo · 2023-11-02 · $441 Meals for Vabysmo · 2023-10-23 · $35 Meals for Vabysmo · 2023-08-23 · $24 Meals for Vabysmo · 2023-07-20 · $34 Meals for Vabysmo · 2023-04-27 · $35 Meals for Vabysmo · 2023-03-23 · $125 Meals for Vabysmo · 2023-03-07 · $25 Meals for Vabysmo · 2023-01-19 · $21 Meals for Susvimo · 2023-01-06 · $25 Meals for Vabysmo · 2023-01-06 · $35
Astellas Pharma US	Izervay	$733	7 payments Meals · 2023-11-27 · $21 Meals · 2023-10-19 · $145 Consulting for Izervay · 2023-10-16 · $500 Meals · 2023-09-15 · $2 Meals · 2023-09-15 · $23 Meals · 2023-09-10 · $9 Meals · 2023-08-11 · $33
Apellis Pharmaceuticals	Syfovre	$524	9 payments Meals for Syfovre · 2023-10-25 · $70 Meals · 2023-10-19 · $34 Meals · 2023-08-30 · $31 Meals · 2023-07-10 · $82 Meals · 2023-06-29 · $31 Meals for Syfovre · 2023-05-25 · $112 Meals · 2023-04-14 · $70 Meals · 2023-04-14 · $60 Meals · 2023-03-29 · $34
Coherus Biosciences	Cimerli	$144	2 payments Meals for Cimerli · 2023-12-12 · $19 Meals for Cimerli · 2023-03-14 · $125
Biogen	None	$122	3 payments Meals · 2023-04-27 · $25 Meals · 2023-03-08 · $80 Meals · 2023-02-02 · $17
Regeneron Pharmaceuticals	Eylea Hd	$40	1 payment Meals for Eylea Hd · 2023-08-23 · $40
Bausch & Lomb Americas	Xipere	$24	1 payment Meals for Xipere · 2023-06-19 · $24
Mallinckrodt Hospital Products	Acthar	$22	1 payment Meals for Acthar · 2023-08-17 · $22
Regeneron Healthcare Solutions	Eylea	$17	1 payment Meals for Eylea · 2023-05-17 · $17

2022: $22,441

Sort by

Payments by company in 2022

Genentech	Susvimo	$9,279	4 payments Meals for Lucentis · 2022-09-30 · $32 Consulting for Susvimo · 2022-07-11 · $3,360 Consulting · 2022-03-10 · $1 Consulting · 2022-03-10 · $5,887
F. Hoffmann-La Roche AG	Susvimo	$7,261	3 payments Consulting for Susvimo · 2022-03-01 · $3,140 Consulting for Susvimo · 2022-01-25 · $2,159 Consulting for Susvimo · 2022-01-24 · $1,963
Genentech USA	Lucentis	$5,762	14 payments Consulting · 2022-12-05 · $1,815 Meals for Vabysmo · 2022-10-18 · $27 Travel for Lucentis · 2022-09-29 · $70 Travel for Lucentis · 2022-09-29 · $72 Meals for Lucentis · 2022-09-29 · $110 Consulting for Lucentis · 2022-09-29 · $3,360 Meals for Susvimo · 2022-09-12 · $21 Meals for Vabysmo · 2022-09-01 · $26 Meals · 2022-06-24 · $23 Meals · 2022-06-10 · $21 Meals for Vabysmo · 2022-05-10 · $23 Meals for Susvimo · 2022-04-12 · $25 Meals for Vabysmo · 2022-03-09 · $150 Meals for Susvimo · 2022-02-01 · $19
Biogen	None	$45	2 payments Meals · 2022-07-20 · $22 Meals · 2022-06-14 · $23
Regeneron Pharmaceuticals	Eylea	$33	1 payment Meals for Eylea · 2022-09-07 · $33
Regeneron Healthcare Solutions	Eylea	$24	1 payment Meals for Eylea · 2022-04-14 · $24
Coherus Biosciences	Cimerli	$21	1 payment Meals for Cimerli · 2022-11-16 · $21
Bausch & Lomb Americas	Lotemax Sm	$15	1 payment Meals for Lotemax Sm · 2022-10-12 · $15

2021: $3,425

Sort by

Payments by company in 2021

Genentech USA	Lucentis	$3,310	8 payments Consulting · 2021-12-14 · $208 Meals for Susvimo · 2021-10-26 · $23 Consulting · 2021-09-29 · $415 Consulting · 2021-07-23 · $2,000 Consulting for Lucentis · 2021-06-30 · $208 Meals for Lucentis · 2021-06-08 · $24 Meals for Lucentis · 2021-04-27 · $18 Consulting for Lucentis · 2021-03-31 · $415
Aerie Pharmaceuticals	Rocklatan	$115	1 payment Meals for Rocklatan · 2021-09-09 · $115

2020: $6,246

Sort by

Payments by company in 2020

Genentech	Lucentis	$4,775	2 payments Consulting for Lucentis · 2020-07-23 · $2,420 Consulting · 2020-07-22 · $2,355
Genentech USA	Lucentis	$1,267	2 payments Consulting for Lucentis · 2020-12-03 · $1,245 Meals for Lucentis · 2020-06-16 · $22
Novartis Pharmaceuticals	Beovu	$123	2 payments Meals for Beovu · 2020-02-13 · $110 Meals for Beovu · 2020-01-09 · $13
Carl Zeiss Meditec AG	None Specified	$39	2 payments Gift for None Specified · 2020-04-22 · $19 Gift for None Specified · 2020-04-03 · $19
Regeneron Healthcare Solutions	Eylea	$22	1 payment Meals for Eylea · 2020-11-13 · $22
Alimera Sciences	Iluvien	$21	1 payment Meals for Iluvien · 2020-09-17 · $21

2019: $11,617

Sort by

Payments by company in 2019

Genentech	Lucentis	$5,941	7 payments Meals for Non-Covered Product · 2019-10-11 · $59 Meals · 2019-10-11 · $73 Meals for Lucentis · 2019-10-10 · $60 Meals for Lucentis · 2019-06-01 · $237 Meals for Lucentis · 2019-05-31 · $122 Consulting for Lucentis · 2019-05-31 · $5,000 Travel for Lucentis · 2019-05-31 · $390
F. Hoffmann-La Roche AG	Lucentis	$5,226	2 payments Paid to speak or teach for Lucentis · 2019-06-30 · $3,429 Paid to speak or teach for Lucentis · 2019-03-31 · $1,798
Genentech USA	Lucentis	$189	2 payments Meals for Lucentis · 2019-11-19 · $18 Meals · 2019-10-11 · $172
Bausch & Lomb a division of Bausch Health US	Envista	$121	1 payment Meals for Envista · 2019-09-23 · $121
AbbVie	Humira	$87	1 payment Meals for Humira · 2019-05-09 · $87
Alimera Sciences	Iluvien	$36	2 payments Meals for Iluvien · 2019-10-21 · $21 Meals for Iluvien · 2019-06-03 · $16
Regeneron Healthcare Solutions	Eylea	$17	1 payment Meals for Eylea · 2019-11-04 · $17

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

Novartis Pharmaceuticals Corporation · A Randomized, Participant and Investigator Masked, Placebo-Controlled, Multicenter, Proof-of-Concept Study To Assess the Safety and Efficacy of Lnp023 (Iptacopan) in Patients With Early and Intermediate Age-Related Macular Degeneration · 2025	Their institution	$3,957,266
Novartis Pharmaceuticals Corporation · A Randomized, Participant and Investigator Masked, Placebo-Controlled, Multicenter, Proof-of-Concept Study To Assess the Safety and Efficacy of Lnp023 (Iptacopan) in Patients With Early and Intermediate Age-Related Macular Degeneration · 2024	Their institution	$1,690,146
Ocular Therapeutix, Inc. · Study To Evaluate the Efficacy and Safety of Intravitreal Otx-Tki (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration · 2025	Their institution	$893,428
Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Masked Phase 3a Study To Assess Safety and Efficacy of Brolucizumab 6 Mg Q4 Weeks Compared To Aflibercept 2 Mg Q4 Weeks in Patients With Neovascular Age Related Macular Degeneration Namd With Persistent Retinal Fluid · 2020	Their institution	$473,522
ModernaTX, Inc. · A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Mrna-1345, An Mrna Vaccine Targeting Respiratory Syncytial Virus (Rsv), in Adults 60 Years of Age · 2022	Their institution	$366,097
Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2021	Their institution	$300,500
Genentech, Inc. · Port Delivery System for Ranibizumab · 2019	Their institution	$252,928
Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2022	Their institution	$249,217
Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2020	Their institution	$247,053
Boehringer Ingelheim Pharmaceuticals, Inc. · A Phase 2 Randomized, Double-Masked, Active-Controlled Study To Evaluate Efficacy and Safety of Two Regimens of Bi 771716 Against Pegcetacoplan in Patients With Geographic Atrophy Secondary To Age-Related Macular Degeneration. · 2025	Their institution	$235,898
Boehringer Ingelheim International GmbH · Crimson: A Multicentre, Randomised, Sham-Controlled (and Active Controlled in the USA), Double-Masked, 72-Week Trial To Study the Safety, Tolerability, Pharmacokinetics, and Efficacy of 3 Dosing Regimens of Intravitreal Bi 764524 in Patients With Moderately Severe To Severe Non-Proliferative Diabetic Retinopathy · 2025	Their institution	$229,199
Genentech, Inc. · A Phase 1 Sad MD in Diabetic Macular Edema · 2025	Their institution	$227,708
Genentech, Inc. · Port Delivery System for Ranibizumab · 2020	Their institution	$225,427
Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Masked Phase 3a Study To Assess Safety and Efficacy of Brolucizumab 6 Mg Q4 Weeks Compared To Aflibercept 2 Mg Q4 Weeks in Patients With Neovascular Age Related Macular Degeneration Namd With Persistent Retinal Fluid · 2019	Their institution	$211,728
Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2020	Their institution	$188,937
Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2025	Their institution	$184,718
Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2023	Their institution	$172,551
Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2022	Their institution	$170,630
Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Masked Phase 3a Study To Assess Safety and Efficacy of Brolucizumab 6 Mg Q4 Weeks Compared To Aflibercept 2 Mg Q4 Weeks in Patients With Neovascular Age Related Macular Degeneration Namd With Persistent Retinal Fluid · 2021	Their institution	$168,528
Genentech, Inc. · Lucentis Fsv4 Lad Amd Ladder · 2019	Their institution	$154,938
Novartis Pharmaceuticals Corporation · A Randomized, Participant and Investigator Masked, Placebo-Controlled, Multicenter, Proof-of-Concept Study To Assess the Safety and Efficacy of Lnp023 (Iptacopan) in Patients With Early and Intermediate Age-Related Macular Degeneration · 2023	Their institution	$152,854
Alexion Pharmaceuticals, Inc. · A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (Alxn2040) in Patients With Geographic Atrophy (Ga) Secondary To Age Related Macular Degeneration (Amd) · 2023	Their institution	$125,350
Boehringer Ingelheim Pharmaceuticals, Inc. · Jade: Phase II Trial in Patients With Geographic Atrophy: A Randomized, Double-Masked, Placebo-Controlled, Dose-Finding Study To Evaluate the Efficacy and Safety of Bi 1584862 · 2025	Their institution	$122,303
Ocular Therapeutix, Inc. · Study To Evaluate the Efficacy and Safety of Intravitreal Otx-Tki (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration · 2024	Their institution	$122,208
Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2023	Their institution	$121,517
Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2024	Their institution	$93,411
ModernaTX, Inc. · A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study To Evaluate the Efficacy, Safety, and Immunogenicity of Mrna-1647 Cytomegalovirus (Cmv) Vaccine in Healthy Participants 16 To 40 Years of Age · 2022	Their institution	$91,579
Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2021	Their institution	$84,116
Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2024	Their institution	$79,697
F. Hoffmann-La Roche AG · Real World Long Term Data Collection for Roche Ophthalmology Products Voyager · 2025	Their institution	$70,928
Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2019	Their institution	$70,636
Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2025	Their institution	$69,772
Regeneron Pharmaceuticals, Inc. · A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe To Severe Nonproliferative Diabetic Retinopathy · 2019	Their institution	$69,721
F. Hoffmann-La Roche AG · Real World Long Term Data Collection for Roche Ophthalmology Products Voyager · 2023	Their institution	$62,378
Alexion Pharmaceuticals, Inc. · A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (Alxn2040) in Patients With Geographic Atrophy (Ga) Secondary To Age Related Macular Degeneration (Amd) · 2024	Their institution	$60,887
Genentech, Inc. · A Phase III Multicenter Observation Comparator Study of the Efficacy Safety and Pharmacokinetics · 2021	Their institution	$60,468
Alexion Pharmaceuticals, Inc. · A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (Alxn2040) in Patients With Geographic Atrophy (Ga) Secondary To Age Related Macular Degeneration (Amd) · 2025	Their institution	$58,977
Genentech, Inc. · Port Delivery System for Ranibizumab · 2023	Their institution	$57,838
Genentech, Inc. · Mad To Assess the Safety Tolerability and Pk Pd in Namd Patients · 2025	Their institution	$56,327
F. Hoffmann-La Roche AG · Real World Long Term Data Collection for Roche Ophthalmology Products Voyager · 2024	Their institution	$52,162
Genentech, Inc. · Belvedere · 2023	Their institution	$46,380
Genentech, Inc. · A Phase III Multicenter Observation Comparator Study of the Efficacy Safety and Pharmacokinetics · 2022	Their institution	$45,761
Genentech, Inc. · Port Delivery System for Ranibizumab · 2021	Their institution	$44,962
Alexion Pharmaceuticals, Inc. · A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (Alxn2040) in Patients With Geographic Atrophy (Ga) Secondary To Age Related Macular Degeneration (Amd) · 2022	Their institution	$43,937
Genentech, Inc. · Port Delivery System of Ranizibumab Extension Study · 2020	Their institution	$40,122
Boehringer Ingelheim International GmbH · A Randomized, Double-Masked, Placebo-Controlled Trial To Evaluate the Efficacy, Safety and Tolerability of Oral Bi1815368 in Participants With Center-Involved Diabetic Macular Edema · 2025	Their institution	$37,585
Genentech, Inc. · Lucentis Fsv4 Lad Amd Ladder · 2020	Their institution	$37,483
Genentech, Inc. · Port Delivery System of Ranizibumab Extension Study · 2019	Their institution	$36,632
Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Masked Phase 3a Study To Assess Safety and Efficacy of Brolucizumab 6 Mg Q4 Weeks Compared To Aflibercept 2 Mg Q4 Weeks in Patients With Neovascular Age Related Macular Degeneration Namd With Persistent Retinal Fluid · 2022	Their institution	$34,687
Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2021	Their institution	$33,781
Genentech, Inc. · A Phase III Multicenter Observation Comparator Study of the Efficacy Safety and Pharmacokinetics · 2025	Their institution	$32,264
Regeneron Pharmaceuticals, Inc. · A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran Or Cemdisiran Alone in Participants With Geographic Atrophy Secondary To Age-Related Macular Degeneration · 2025	Their institution	$31,501
Genentech, Inc. · Port Delivery System of Ranizibumab Extension Study · 2021	Their institution	$30,609
Genentech, Inc. · A Phase III Multicenter Observation Comparator Study of the Efficacy Safety and Pharmacokinetics · 2024	Their institution	$29,674
Genentech, Inc. · Belvedere · 2024	Their institution	$25,613
Genentech, Inc. · A Phase III Multicenter Observation Comparator Study of the Efficacy Safety and Pharmacokinetics · 2020	Their institution	$24,814
Genentech, Inc. · A Phase IV, Multicenter, Open-Label Study To Assess Corneal Endothelial Cells in Patients With Neovascular Age-Related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (Pds) (Belvedere) · 2025	Their institution	$24,619
Novartis Pharmaceuticals Corporation · A Randomized, Participant and Investigator Masked, Placebo-Controlled, Multicenter, Proof-of-Concept Study To Assess the Safety and Efficacy of Lnp023 (Iptacopan) in Patients With Early and Intermediate Age-Related Macular Degeneration · 2022	Their institution	$22,553
Genentech, Inc. · A Phase III Multicenter Observation Comparator Study of the Efficacy Safety and Pharmacokinetics · 2023	Their institution	$20,850
Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2022	Their institution	$18,594
Boehringer Ingelheim International GmbH · Bi 764524 Phase 2b · 2024	Their institution	$16,950
Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2023	Their institution	$12,952
ABBVIE INC. · Study To Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (Namd) · 2025	Their institution	$11,162
F. Hoffmann-La Roche AG · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2024	This clinician	$8,957
F. Hoffmann-La Roche AG · A Phase II Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration · 2020	This clinician	$8,510
ABBVIE INC. · Long-Term Follow-Up Study of Rgx-314 and Fellow Eye Substudy · 2025	Their institution	$7,003
F. Hoffmann-La Roche AG · Pds Phase 3 Archway · 2021	This clinician	$6,689
F. Hoffmann-La Roche AG · A Phase III Multicenter Observation Comparator Study of the Efficacy Safety and Pharmacokinetics · 2024	This clinician	$6,454
Genentech, Inc. · Port Delivery System for Ranibizumab · 2022	Their institution	$6,265
Mylan Technologies Inc. · A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study To Evaluate the Efficacy and Safety of Myl-1701p and Eylea in Subjects With Diabetic Macular Edema · 2021	Their institution	$5,373
Boehringer Ingelheim International GmbH · A Phase 2 Randomized, Double-Masked, Active-Controlled Study To Evaluate Efficacy and Safety of Two Regimens of Bi 771716 Against Pegcetacoplan in Patients With Geographic Atrophy Secondary To Age-Related Macular Degeneration. · 2025	Their institution	$5,129
F. Hoffmann-La Roche AG · Pds Endophthalmitis Case Series · 2024	This clinician	$4,645
F. Hoffmann-La Roche AG · Patient Preference and Treatment Satisfaction in Patients Treated for Namd Using the Port Delivery System for Ranibizumab Pds · 2022	This clinician	$4,634
Novartis Pharmaceuticals Corporation · A 64-Week, Phase 3b, Multi-Center Study Assessing the Efficacy and Safety of Brolucizumab 6mg Compared To Aflibercept 2mg in A Treat To Control Regimen in Patients With Neovascular Age-Related Macular Degeneration · 2020	Their institution	$4,398
Boehringer Ingelheim International GmbH · Jade: Phase II Trial in Patients With Geographic Atrophy: A Randomized, Double-Masked, Placebo-Controlled, Dose-Finding Study To Evaluate the Efficacy and Safety of Bi 1584862 · 2025	Their institution	$3,132
F. Hoffmann-La Roche AG · Hemoglobin A1c Methods and Reporting in Pivotal Diabetes Eye Trials Over Time and Compared To Other Major Diabetes Trials · 2023	This clinician	$2,635
F. Hoffmann-La Roche AG · Technical Updates To Port Delivery System With Ranibizumab (Pds) and Clinical Experience With Updated Refill Needle · 2024	This clinician	$1,751
F. Hoffmann-La Roche AG · Port Delivery System of Ranibizumab Extension Study · 2024	This clinician	$1,377
Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2022	This clinician	$1,260
ABBVIE INC. · Long-Term Follow-Up Study of Rgx-314 and Fellow Eye Substudy (Rgx-314 Srltfu) · 2025	Their institution	$1,200
F. Hoffmann-La Roche AG · A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema Pagoda · 2021	This clinician	$1,084
F. Hoffmann-La Roche AG · The Return of Pds: Port Delivery System With Ranibizumab Is Back To Enable Continuous Delivery of Anti-Vegf Therapy for Patients With Namd Dme and Dr · 2024	This clinician	$1,040
F. Hoffmann-La Roche AG · Technical Updates To Port Delivery System With Ranibizumab (Pds) for the Treatment of Neovascular Age-Related Macular Degeneration (Namd), Diabetic Macular Edema (Dme), and Diabetic Retinopathy (Dr) · 2024	This clinician	$970
Novartis Pharmaceuticals Corporation · An Open-Label, Single Arm, Multiple Dose Study To Investigate Safety, Pharmacokinetics and Immunogenicity of New Formulation of Rth258 in Pre-Treated Patients With Neovascular Age-Related Macular Degeneration · 2019	Their institution	$677
F. Hoffmann-La Roche AG · Mitigation of Endoph: Surgical Evolution · 2024	This clinician	$602
F. Hoffmann-La Roche AG · The Return of Pds: Port Delivery System With Ranibizumab Is Back To Enable Continuous Delivery of Anti-Vegf Therapy for Patients With Namd, Dme, and Dr · 2023	This clinician	$480
F. Hoffmann-La Roche AG · Technical Updates To the Port Delivery System With Ranibizumab for the Treatment of Neovascular Age-Related Macular Degeneration Diabetic Macular Edema and Diabetic Retinopathy · 2024	This clinician	$259
Genentech, Inc. · Real World Long Term Data Collection for Roche Ophthalmology Products Voyager · 2024	Their institution	$198
Mylan Inc. · A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study To Evaluate the Efficacy and Safety of Myl-1701p and Eylea in Subjects With Diabetic Macular Edema · 2021	Their institution	$31

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 100.0 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1477504405
Licence: CA A103453, MD D64111California A103453: Current · expires 2027-07-31
Trained: University of Missouri, Columbia School of Medicine, 2002 · 24 years ago
Group: Vitreo-Retinal Medical Group, Inc.
Gender: Female

More record details

Sole proprietor: No
Taxonomy: Federal specialty code 207WX0107X (207WX0107X); Federal specialty code 207W00000X (207W00000X)
Mailing address: 3939 J St, Ste 104, Sacramento, CA, 95819
NPI first listed: 2006-05-15
NPI last updated: 2017-04-02

This is when the NPI record was last certified, not a medical board exam.